Many clinical trials for lupus are starting up around the country. The following list represents a number of studies that the LRI has been notified or is aware of, and is sorted by location to make it easy to see what’s happening in your area. While no one source is comprehensive, extensive trial listings also are available on clinicaltrials.gov and on the LRI Clinical Resources center developed in partnership with Thomson CenterWatch. If you see a trial that interests you, scroll down to the bottom for contact information. Do not contact the Lupus Research Institute for study details. Please visit back soon, as a number of major clinical trials are starting soon, and trial locations currently are being determined.
Alabama
Birmingham: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Huntsville: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
La Jolla: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Los Angeles: Triptorelin for Ovary Protection in Childhood Onset Lupus Los Angeles: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
San Francisco: Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m (RG2077) San Francisco: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
San Leandro: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Denver - Epratuzumab in Systemic Lupus Erythematosus – Study Denver - Cognitive Function in SLE: MRI and MRS Correlates
Miami: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Atlanta: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Atlanta: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Chicago: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Chicago: Triptorelin for Ovary Protection in Childhood Onset Lupus
Muncie: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
New Orleans: Ultraviolet A-1 Light Therapy for SLE
Baltimore: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Baltimore: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Bethesda: Monoclonal Antibody to IL-6 Receptor Bethesda: Sirolimus Therapy in Ideopathic and Lupus Membranous Nephrology Bethesda: Pathogenesis and Natural History of SLE Bethesda: Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe SLE
Boston: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Ann Arbour: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Rochester: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Columbia: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis
Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York
Brooklyn: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Lake Success: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Antiphospholipid Syndrome Collaborative Registry (APSCORE) Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m (RG2077) Triptorelin for Ovary Protection in Childhood Onset Lupus ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis North Carolina
Chapel Hill: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis. Chapel Hill: Antiphospholipid Syndrome Collaborative Registry (APSCORE) Durham: Antiphospholipid Syndrome Collaborative Registry (APSCORE) Durham: Atherosclerosis Prevention Using Atrovistatin in Children with SLE (APPLE)
Cinncinati: Triptorelin for Ovary Protection in Childhood Onset Lupus Cleveland: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Columbus: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Columbus: Triptorelin for Ovary Protection in Childhood Onset Lupus
Oklahoma City: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Anti-CD20 (Rituxan)
Philadelphia: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis.
Pittsburgh: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis Pittsburgh: Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus
Charleston: Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus Charleston: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis.
Dallas: ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis San Antonio: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Salt Lake City: Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Seattle: - - Triptorelin for Ovary Protection in Childhood Onset Lupus
Milwaukee: Triptorelin for Ovary Protection in Childhood Onset Lupus
Wyoming LRI List of Clinical Trials ALMS—Aspreva Lupus Management Study of Mycophenolate Mofetil (MMF) in Lupus Nephritis. Sponsor: Aspreva Phamaceuticals (as part of the Roche-Aspreva Collaboration Agreement) Seeking Volunteers: Persons with a diagnosis of lupus nephritis requiring immunosuppressive therapy. Contact Info: medinfo@aspreva.com Anti-CD20 (Rituxan) Sponsor: Genentech/IDEC Pharmaceuticals Seeking Volunteers: People age 16 to 75 with moderate to severe lupus Lupus patients with organ involvement Contact Info: Genentech Clinical Trial Information Support Line 888-662-6728; many trial sites are currently being determined. In Philadelphia: Felecia 215-615-4306. Antiphospholipid Syndrome Collaborative Registry (APSCORE) Sponsor: National Institutes of Health/NIAMS, Bethesda, MD Seeking Volunteers: People with antiphospholipid antibodies to joint a national disease registery. Contact info: Robert S. Roubey, M., or Gail Buxton: 919-966-0572; 800-411-1222;
Atherosclerosis Prevention Using Atrovistatin in Children with SLE (APPLE) Sponsor: National Institutes of Health/NIAMS Bethesda, MD Seeking Volunteers: Children with lupus under age 19. Contact info: Craig McLendon 919-668-8140 Cognitive Function in SLE: MRI and MRS Correlates Sponsor: National Jewish Medical and Research Center; University of Colorado Health Sciences Center, Denver CO (funded by NIH/NIAMS) Seeking Volunteers: Individuals between ages 18-59 with a diagnosis of SLE, either with and without cognitive dysfunction; no history of major neurologic (ie, head injury, stroke, seizures) or psychiatric disorders. Contact info: Elizabeth Kozora, PhD, ABPP 303-398-1141; Epratuzumab in Systemic Lupus Erythematosus - Pharmacokinetics Study Sponsor: Immunomedics, Inc.
Seeking Volunteers: Persons age 18 and above who have had SLE for at least 6 months prior to study, has at least one elevated autoantibody at study entery, and has moderaly active SLE disease at study entry. Contact info: Heather Horne 973-727-7589 Epratuzumab in Systemic Lupus Erythematosus – Study Sponsor: Immunomedics, Inc. Seeking Volunteers: Persons age 18 and above who has had SLE for at least 6 months with at least one elevated lupus-associated antibody, and has new onset severe lupus disease flare in at least one organ/system, OR has a moderate lupus disease flare in several body ogans/systems. Contact info: Sally Klemm, RN. 973-605-8022 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe SLE Sponsor: National Institutes of Health/NCI, Bethesda, MD Seeking Volunteers: Patients between ages of 15 and 40 with severe lupus Contact info: Patients Recruitment and Public Liaison Office: 800-411-1222;
Sirolimus Therapy in Ideopathic and Lupus Membranous Nephrology Sponsor: Wyeth –Ayerst Laboratories & National Institutes of Health/NIDDK, Bethesda, MD Seeking Volunteers: Persons 13 or older with persistent proteinuria despite standard treatment for at least one month with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Contact info: Patients Recruitment and Public Liaison Office: 800-411-1222; Monoclonal Antibody to IL-6 Receptor Sponsor: National Institutes of Health/NIAMS, Bethesda, MD Seeking Volunteers: People with mild to moderate SLE. Contact info: Patient Recruitment and Public Liaison Office 800-411-1222; prpl@mail.cc.nih.gov Pathogenesis and Natural History of SLE Sponsor: National Institutes of Health/NIAMS, Bethesda, MD Seeking Volunteers: People 10 years and older with known or suspected SLE, and their relatives. Contact info: Patient Recruitment and Public Liaison Office 800-411-1222; prpl@mail.cc.nih.gov Sponsor: Fred Hutchinson Cancer Research Center, Seattle WA
Seeking Volunteers: Individuals between 2 and 18, with at least one ACR criterion for severe juvenile rheumatoid arthritis, juvenile SLE, systemic sclerosis dermatomyositis. Contact info: Ann Woolfrey, MD. 206-667-4453 Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m (RG2077) Sponsor: National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network Seeking Volunteers: Persons age 18 and above with lupus nephritis. Also, people with SLE and on concurrent treatment with intravenous cyclophosphamide for certain manifestations of lupus. Also: stable medication regiment for at least 4 weeks prior to study entry, weight between 88.2 lb and 275.6 lb, and willing to use acceptable forms of contraception. Contact info: San Francisco: 415-502-1886; New York City: 212-305-9986 Triptorelin for Ovary Protection in Childhood Onset Lupus Sponsor: FDA Office of Orphan Products Development Seeking Volunteers: Females between ages 9 and 21 years, not pregnant, who have lupus and are newly requiring IV cyclophosphamide. Contact info: Hermine Brunner, MD. 513-636-5484; Ultraviolet A-1 Light Therapy for SLE Sponsor: National Center for Research Resources/Louisiana State University, New Orleans LA Seeking Bolunteers: Patients age 15-70 with symptomatic SLE Contact info: GRCR 504-568-4609 Disclaimer
This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted. Posted on June 22, 2005.
Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery Updated information and services can be found at: References This article cites 25 articles, 8 of which can be accessed free at: Rapid responses 8 rapid responses have been posted to this article, which you can access forfree at: Email alerting Receive free email alerts
Copyright Ó Blackwell Munksgaard 2004Ephedra alkaloids and brief relapse inEMDR-treated obsessive compulsivedisorderFluvoxamine with no compulsive hand washing and no mooddisturbance. In his review of the adverse effects of some herbal medicines,While there is still debate about the mechanism of action ofErnst (1) draws attention to reports that ma-huang, a herbalEMDR in post-traumatic s